FG
VTGN icon

Fairman Group’s VistaGen Therapeutics VTGN Stock Holding History

Fairman Group’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7 Hold
29
– – ﹤0.01% 332
2026
Q1 		$17 Hold
29
– – ﹤0.01% 325
2025
Q4 		$19 Hold
29
– – ﹤0.01% 331
2025
Q3 		$103 Hold
29
– – ﹤0.01% 268
2025
Q2 		$58 Hold
29
– – ﹤0.01% 253
2025
Q1 		$86 Hold
29
– – ﹤0.01% 253
2024
Q4 		$86 Hold
29
– – ﹤0.01% 340
2024
Q3 		$87 Hold
29
– – ﹤0.01% 392
2024
Q2 		$101 Hold
29
– – ﹤0.01% 392
2024
Q1 		$153 Hold
29
– – ﹤0.01% 384
2023
Q4 		$149 Buy
+29
New +$110 ﹤0.01% 379

Other funds holding VTGN

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CWS
Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return

Fairman Group's VTGN Position: Q2 2026 in Review

Fairman Group held its VistaGen Therapeutics (VTGN) position steady in Q2 2026 at 29 shares worth $7. The position accounts for ﹤0.01% of the portfolio, ranked #332.

Fairman Group first reported a position in VTGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $153 in Q1 2024. 26 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Fairman Group held 29 shares of VistaGen Therapeutics worth $7 as of Q2 2026.
  • Fairman Group left its VistaGen Therapeutics share count unchanged in Q2 2026.
  • VistaGen Therapeutics made up ﹤0.01% of Fairman Group's portfolio in Q2 2026, its #332 holding.
  • Fairman Group first reported a position in VistaGen Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Fairman Group's VistaGen Therapeutics position peaked at $153 in Q1 2024.
  • 26 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Fairman Group's 13F filing for Q2 2026, filed 4 Aug 2026.